Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (2914)	10/12/2011 12:11:58 PM
From: Grantcw	Read Replies (1) \| Respond to of 7243

I wish it was my biggest disaster this year! :) I've for some reason had several. Nothing earth shattering, but not a good year for me, especially compared to the last two. Yes, I like the orphan drug status. I'm no expert, but I also think that it's not really a drug that generic companies would be really trying to jump into. There's side-effect potential and not a lot of patients. But, I'm hoping SVNT is about to get a J code for KRYSTEXXA for the new year, which hopefully will get a ramp up going. The thing is, at $50k/year, there's not a lot of patients needed to justify this market cap. I think the word is out there after the last year of salesmen being out on the road. And my hunch is that the drug is still working pretty well for a limited number of patients. So, my view is that it's just a high-price issue, and once we get that figured out with the insurance, I think we're in business to at least get a few thousand clients, which will justify the market cap. I think DNDN is running into the same issues. And there's Europe as you mentioned. I think there's decent hope for this one, and they should have the cash to play out the ramp-up. We'll see though... -Grant